Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
批准号:
8710116
负责人:
RONALD T. MITSUYASU
金额:
$15.48万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-01 至 2016-07-31
关键词:
AIDS Malignancy ConsortiumAcquired Immunodeficiency SyndromeAffectAwarenessBlood specimenBreastCD4 Lymphocyte CountCancer CenterCancer HospitalCancer PatientCancer Prevention TrialCervicalClinicClinicalClinical TreatmentClinical TrialsCollaborationsComorbidityCross-Sectional StudiesDataDatabasesDevelopmentEarly DiagnosisEducational process of instructingEnrollmentEnvironmental ExposureEpidemiologyFrequenciesFundingFutureGoalsGrantHIVHIV InfectionsHIV riskHealthHospital ReferralsIncidenceIndiaIndividualInfectionInstitutesInstitutionInvestigationLaboratoriesMalignant NeoplasmsMedicalMonitorMorbidity - disease rateOncogenic VirusesOutcomePatientsPeripheral Blood Mononuclear CellPersonsPlasmaPopulationPrevalencePrevention strategyPreventive InterventionProstateRegional CancerRegistriesResearchResearch PersonnelResourcesRiskRisk FactorsScienceScreening for cancerServicesSourceSpecimenStagingSurveysTherapeuticTherapeutic InterventionTissue BankingTissue BanksTreatment outcomeViralViral EpidemiologyViral Load resultbasecancer riskcancer therapycancer typecohortdemographicsfollow-upimprovedmortalityneoplasm registryprofessorprospectivepublic health relevancerepositoryresidencesample collectiontumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Globally, India has one of the largest populations of HIV-infected people, estimated at 2.40 million individuals. Malignancy is a known co-morbidity of HIV infection and is growing in proportion in many parts of the world. The incidence and manifestations of cancer in HIV-infected individuals in India has not yet been well characterized, and the proportion of patients with undiagnosed HIV infection who may be presenting with cancer as their first manifestation of HIV infection is not known. The goal of this proposal is to obtain information on the prevalence of HIV in the cancer population seen over a 1-2 year period at a major cancer treatment and referral center in Northern India. We will similarly assess the HIV prevalence of patients presenting to cancer screening clinics at the same institution (e.g. breast, cervical and prostate). Another goal is to collect information; demographics, HIV and clinical status at presentation, HIV and cancer risk factors, as well as information on incidence of cancer, cancer types, stage, treatments and treatment outcomes in patients with HIV and cancer. In addition we will similarly assess various cancer risk factors and the prevalence of various oncogenic viruses in patients with incident cancers (compared to concurrent control HIV+ individuals from the same HIV clinic at the same institution that do not develop cancer in the timeframe of this study. This will allow assessment of HIV prevalence in various cancers types as well as provide information on the short- term cancer incident and various risk factors and co-factors for cancer development among HIV-infected persons. Identified cancer and HIV individuals from this study will be enrolled in a cancer and HIV registry
and specimen/tissue bank, which we will help establish, for prospective follow-up and specimen collection to obtain data on cancer and HIV treatments and clinical outcomes and to provide a cohort for future research studies, including epidemiologic, laboratory and possible clinical trial. Establishment of the HIV and cancer registry with collected tumor and blood specimens will provide our Indian investigator colleagues with a valuable resource for further research (with additional future Indian outside funding). This study will involve a collaboration between investigators at UCLA, the All India Institute for Medical Sciences (AIIMS) in New Delhi and the Dr. B.R. Ambedkar Institute and Rotary Cancer Hospital (DR BRAIRCH) at AIIMS The overall goal is to better characterize the important association of HIV and cancer in India and to identify
risk factors and potential viral co-factors which may ultimately service as the basis for future therapeutic and prevention interventions for this important co-morbidity in HIV.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
-
批准号:8539193
-
项目类别:
-
资助金额:$16.51万
-
财政年份:2013
-
负责人:RONALD T. MITSUYASU
-
依托单位:
South American Prevention of HIV Research Training Program (SAPHIR)
-
批准号:8474842
-
项目类别:
-
资助金额:$25.33万
-
财政年份:2011
-
负责人:RONALD T. MITSUYASU
-
依托单位:
South American Prevention of HIV Research Training Program (SAPHIR)
-
批准号:8209934
-
项目类别:
-
资助金额:$25.2万
-
财政年份:2011
-
负责人:RONALD T. MITSUYASU
-
依托单位:
South American Prevention of HIV Research Training Program (SAPHIR)
-
批准号:8309930
-
项目类别:
-
资助金额:$26.76万
-
财政年份:2011
-
负责人:RONALD T. MITSUYASU
-
依托单位:
AMC Group Chairman, University of California, LA
-
批准号:8099873
-
项目类别:
-
资助金额:$48.08万
-
财政年份:2010
-
负责人:RONALD T. MITSUYASU
-
依托单位:
Network Core Research Lab
-
批准号:8099897
-
项目类别:
-
资助金额:$41.79万
-
财政年份:2010
-
负责人:RONALD T. MITSUYASU
-
依托单位:
UCLA-USC Combined Los Angeles Core Site
-
批准号:8099881
-
项目类别:
-
资助金额:$41.79万
-
财政年份:2010
-
负责人:RONALD T. MITSUYASU
-
依托单位:
A SINGLE ARM, OPEN-LABEL PILOT TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A QUADR
-
批准号:7951594
-
项目类别:
-
资助金额:$9.4万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
PHASE IIA TRIAL OF 1% TOPICAL CIDOFOVIR FOR TREATMENT OF HIGH-GRADE PERIANAL SQU
-
批准号:8167120
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
A PHASE II TRIAL OF COMBINED MODALITY THERAPY PLUS CETUXIMAB IN HIV-ASSOCIATED A
-
批准号:8167098
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
A PHASE II TRIAL OF DOXIL, RITUXIMAB, CYCLOPHOSPHAMIDE,
-
批准号:7951572
-
项目类别:
-
资助金额:$1.32万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
SHORT COURSE REGIMEN (R-CODOX-M/IVAC) I
-
批准号:7951574
-
项目类别:
-
资助金额:$0.73万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
DOUBLE-BLIND PHASE II STUDY OF MULTIPLE DOSES OF PALIFERMIN (RHUKGF) FOR AIDS
-
批准号:7951580
-
项目类别:
-
资助金额:$4.99万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
A PHASE II TRIAL OF DOXIL, RITUXIMAB, CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNIS
-
批准号:8167102
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
PHASE IIA TRIAL OF 1% TOPICAL CIDOFOVIR FOR TREATMENT OF HIGH-GRADE PERIANAL SQU
-
批准号:7951592
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
A PROSPECTIVE PHASE II STUDY OF A HIGH DOSE, SHORT COURSE REGIMEN (R-CODOX-M/IVA
-
批准号:8167104
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
A SINGLE ARM, OPEN-LABEL PILOT TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A QUADR
-
批准号:8167122
-
项目类别:
-
资助金额:$9.41万
-
财政年份:2009
-
负责人:RONALD T. MITSUYASU
-
依托单位:
A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE
-
批准号:7717987
-
项目类别:
-
资助金额:$0.35万
-
财政年份:2007
-
负责人:RONALD T. MITSUYASU
-
依托单位:
AMC 036: A PHASE II TRIAL OF TOPICAL HALOFUGINONE IN PATIENTS WITH HIV RELAT
-
批准号:7718000
-
项目类别:
-
资助金额:$0.53万
-
财政年份:2007
-
负责人:RONALD T. MITSUYASU
-
依托单位:
A PHASE II TRIAL OF IMATINIB MESYLATE (GLEEVEC) IN PATIENTS WITH HIV RELATED
-
批准号:7606810
-
项目类别:
-
资助金额:$0.89万
-
财政年份:2007
-
负责人:RONALD T. MITSUYASU
-
依托单位:
海外基金